Scienmag
NOVEMBER 12, 2020
Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.
Pharmaceutical Technology
MAY 25, 2023
The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The London School of Hygiene and Tropical Medicine (LSHTM) also highlights the urgent need for a vaccine against the meningococcal X strain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
JANUARY 14, 2021
14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. HOUSTON – (Jan.
Pharmaceutical Technology
NOVEMBER 11, 2022
The latest development comes after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided a positive opinion on vaccine use. The vaccine elicited a robust immune response against several variants in registrational trials conducted when the Omicron variant of the virus was dominant.
Rethinking Clinical Trials
APRIL 18, 2023
There are many hypothesized causes that may co-exist in the same patient, such as persistent virus or antigens, reactivation of other viruses, uncontrolled immune responses, damage to a wide range of organs and tissues, and injury to blood vessels and abnormal blood clotting. The first trial will begin enrolling in July 2023.
XTalks
DECEMBER 12, 2023
Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. When people think about innovation drivers in global healthcare, they often think of “big pharma,” and not necessarily companies in the plasma medicines space.
The Pharma Data
AUGUST 16, 2021
Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.
Expert insights. Personalized for you.
75 
Let's personalize your content